ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE

10045 reported adverse events

Drug classes: Cytochrome P450 3A Inhibitor [EPC] Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC] Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

These side effects are most commonly reported by patients taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE:

# Side effect Count
0 BONE DENSITY DECREASED 4545
1 CHRONIC KIDNEY DISEASE 2641
2 BONE LOSS 2432
3 OSTEONECROSIS 2397
4 TOOTH LOSS 2280
5 MULTIPLE FRACTURES 2144
6 RENAL FAILURE 2119
7 OSTEOPOROSIS 1952
8 RENAL INJURY 1931
9 PAIN 1867
See all common reactions for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE

ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 SYSTEMIC VIRAL INFECTION 3 0.2143
1 BONE DEMINERALISATION 199 0.1879
2 BONE LOSS 2432 0.1616
3 SKELETAL INJURY 1662 0.1605
4 BONE DENSITY DECREASED 4545 0.1449
5 MULTIPLE FRACTURES 2144 0.1304
6 TOOTH LOSS 2280 0.1099
7 CIRCULATING ANTICOAGULANT 2 0.1053
8 TOOTH INJURY 421 0.0969
9 HIV-ASSOCIATED NEUROCOGNITIVE DISORDER 10 0.0901
See all enriched reactions for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE